CYP2C19 and transient ischemic attack: For patients with non-cardioembolic minor IS (NIHSS score ≤3) or high-risk TIA (ABCD2 score ≥4) who present within 24 hours of symptoms onset, it is recommended considering CYP2C19 genetic rapid testing to determine if the patient carries CYP2C19 LoF alleles. The results of this genetic testing will aid in selecting antiplatelet agents.